{"page":{"totalFilteredElements":344},"studies":[{"active":true,"description":"AML-Register und Biomaterialdatenbank der Studienallianz Leuk&#228;mie (SAL) und der AML Cooperative Group (AML-CG)","eudractNumber":null,"id":5759,"indications":[{"id":"leu","name":"Leukämien"},{"id":"leu2","name":"Akute myeloische Leukämie (AML)"}],"mutations":[],"nctNumber":null,"phase":null,"recruitmentStart":"2019-04-29T12:55:09+02:00","shortTitle":"Klinisches AML-Register (SAL, AML-CG)","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"Analyse des Gesamt- und Tumorfreien &#220;berlebens von Patienten mit Kolonkarzinomen als indirekter Parameter der Chemotherapie-Effektivit&#228;t einer definierten Chemotherapie in Abh&#228;ngigkeit von der anatomischen Lokalisation des Prim&#228;rtumors im adjuvanten Ansatz.","eudractNumber":null,"id":8311,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2014-06-01T08:18:06+02:00","shortTitle":"Kolonsegment(Chemo)-Studie","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"KRANIOPHARYNGEOM Registry 2019<br />Multicenter registry for patients with childhood-onset craniopharyngioma, xanthogranuloma, cysts of Rathke&#8217;s pouch, meningioma, pituitary adenoma, arachnoid cysts<br />","eudractNumber":null,"id":5462,"indications":[{"id":"ped","name":"Kindliche Tumoren (inkl. Gehirntumoren und Leukämien)"},{"id":"ped3","name":"Hirntumore (Tumore des zentralen Nervensystems)"},{"id":"ped4","name":"Weitere solide Tumore"}],"mutations":[],"nctNumber":"NCT04158284","phase":null,"recruitmentStart":"2019-10-01T10:52:57+02:00","shortTitle":"Kraniopharyngeom Registry 2019","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"International cooperative treatment protocol for children and adolescents with lymphoblastic lymphoma<br />","eudractNumber":"2017-001691-39","id":4245,"indications":[{"id":"ped","name":"Kindliche Tumoren (inkl. Gehirntumoren und Leukämien)"},{"id":"ped2","name":"Lymphome"},{"id":"ped4","name":"Weitere solide Tumore"}],"mutations":[],"nctNumber":"NCT04043494","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2020-07-04T09:33:15+02:00","shortTitle":"LBL 2018","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"Deutsches Register f&#252;r Langerhanszell Histiozytosen im Kinder- und Jugendalter<br />","eudractNumber":null,"id":1327,"indications":[{"id":"ped","name":"Kindliche Tumoren (inkl. Gehirntumoren und Leukämien)"},{"id":"ped4","name":"Weitere solide Tumore"},{"id":"ped5","name":"Weitere Bluterkrankungen / weitere hämatologische Erkrankungen"}],"mutations":[],"nctNumber":null,"phase":null,"recruitmentStart":"2013-11-04T15:48:41+01:00","shortTitle":"LCH-Reg-DE 2013","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"Li-Fraumeni-Syndrome-CAncer-Predisposition-Syndrome Registry 01<br />","eudractNumber":null,"id":3633,"indications":[{"id":"sar","name":"Sarkome"},{"id":"sar1","name":"Knochensarkome (Ewing-Sarkom, Osteosarkom etc.)"},{"id":"sar2","name":"Weichteilsarkome (Liposarkom, Leiomyosarkom, etc.)"},{"id":"ped","name":"Kindliche Tumoren (inkl. Gehirntumoren und Leukämien)"},{"id":"ped1","name":"Leukämien"},{"id":"ped2","name":"Lymphome"},{"id":"ped3","name":"Hirntumore (Tumore des zentralen Nervensystems)"},{"id":"ped4","name":"Weitere solide Tumore"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_13","name":"Therapieoptimierung"},"recruitmentStart":"2017-08-16T13:09:02+02:00","shortTitle":"LFS-CPS-Registry 01","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Phase II neoadjuvant study evaluating capivasertib plus fulvestrant vs fulvestrant in patients with with primary high-risk lobular breast cancer - LOBSTER","eudractNumber":"2023-509292-17-00","id":9924,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"}],"mutations":[{"name":"ER (Östrogenrezeptor)","id":"mt_248"},{"name":"ER+","id":"mt_47"},{"name":"HER2/neu","id":"mt_19"},{"name":"HER2-","id":"mt_285"},{"name":"PgR (Progesteronrezeptor)","id":"mt_221"},{"name":"PgR+","id":"mt_49"}],"nctNumber":"NCT06607757","phase":{"id":"ph_7","name":"Phase II"},"recruitmentStart":"2024-12-11T09:38:51+01:00","shortTitle":"LOBSTER","therapeutical":true,"therapyLines":[{"id":"tl_7","name":"Neoadjuvant"}]},{"active":true,"description":"LOGGIC Core Bio Clinical Data Bank<br /><div>Registry for molecular and clinical data for patients with low grade glioma (LGG)<br /></div>","eudractNumber":null,"id":4936,"indications":[{"id":"ped","name":"Kindliche Tumoren (inkl. Gehirntumoren und Leukämien)"},{"id":"ped3","name":"Hirntumore (Tumore des zentralen Nervensystems)"},{"id":"ped4","name":"Weitere solide Tumore"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2019-04-01T09:40:34+02:00","shortTitle":"LOGGIC-Core","therapeutical":false,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"A Phase 3, Randomized, International Multicenter Trial for Patients with Pediatric Low Grade Glioma Harboring an Activating RAF Alteration Requiring First-Line Systemic Therapy<div>DAY101-002</div>","eudractNumber":"2022-001363-27","id":9326,"indications":[{"id":"ped","name":"Kindliche Tumoren (inkl. Gehirntumoren und Leukämien)"},{"id":"ped3","name":"Hirntumore (Tumore des zentralen Nervensystems)"},{"id":"ped4","name":"Weitere solide Tumore"}],"mutations":[{"name":"RAF (rapidly accelerated fibrosarcoma)","id":"mt_222"},{"name":"BRAF","id":"mt_9"},{"name":"BRAF V600","id":"mt_5"}],"nctNumber":"NCT05566795","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2024-02-20T09:24:30+01:00","shortTitle":"LOGGIC/Firefly-2","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"Liquid Biopsy als Biomarker unter PSMA-Radioligandentherapie","eudractNumber":null,"id":11461,"indications":[{"id":"pro","name":"Prostatakrebs"}],"mutations":[],"nctNumber":"NCT07118436","phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2025-05-01T09:40:08+02:00","shortTitle":"LOOPS","therapeutical":false,"therapyLines":[]}]}